CYBN - Cybin

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Cybin to lay off 15% employees for cost savings
• Cybin Inc reports Q3 results
• Cybin gets regulatory OK to begin dosing psychedelic-derived drug in humans
• Cybin selects generalized anxiety disorder as target indication for CYB004
• Cybin reports FQ2 results
• Booker again pushes for easier access to psychedelics for terminally ill patients
• Cybin gains on licensing deal for psychedelic based medications
• Rep. Blumenauer talks up 'real potential' of psychedelics as mental health therapies
• Cybin spikes as dosing begins in depression trial for psychedelic therapy
• DEA drops plans to ban more psychedelic compounds
• Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder
• MindMed surge ends as stock flat in Friday trading
• MindMed closes up 36% as it appears to be following in Bed Bath & Beyond's footsteps
• Cybin gains 13% on regulatory nod to study depression candidate
• Cybin stock jumps on announcing at-the-market equity program for up to $35M
• Cybin reports FQ1 results
• Clinilabs starts enrollment in partner Cybin's trial for psilocybin candidate for depression
• Cybin gets FDA green light to begin clinical trial of psilocybin candidate for depression
• Cybin reports FY results
• Cybin rises on institutional review board approval to begin psilocybin-based depression drug trial